ONCODES.PREC.MED. EO-34 (ZR8) - Net Assets

Latest as of : €- EUR ≈ $- USD

Based on the latest financial reports, ONCODES.PREC.MED. EO-34 (ZR8) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-
% of Total Assets	0%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	128.79

ONCODES.PREC.MED. EO-34 - Net Assets Trend (2021–2024)

This chart illustrates how ONCODES.PREC.MED. EO-34's net assets have evolved over time, based on quarterly financial data. Also explore ONCODES.PREC.MED. EO-34 assets under control for the complete picture of this company's asset base.

Annual Net Assets for ONCODES.PREC.MED. EO-34 (2021–2024)

The table below shows the annual net assets of ONCODES.PREC.MED. EO-34 from 2021 to 2024. For live valuation and market cap data, see ONCODES.PREC.MED. EO-34 (ZR8) market capitalisation.

Year	Net Assets	Change
2024-12-31	€-429.39K ≈ $-502.00K	-111.63%
2023-12-31	€3.69 Million ≈ $4.31 Million	-68.67%
2022-12-31	€11.78 Million ≈ $13.77 Million	+180.51%
2021-12-31	€4.20 Million ≈ $4.91 Million	--

Equity Component Analysis

This analysis shows how different components contribute to ONCODES.PREC.MED. EO-34's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 1258713733.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	€15.10 Million	%
Total Equity	€-429.39K	100.00%

ONCODES.PREC.MED. EO-34 Competitors by Market Cap

The table below lists competitors of ONCODES.PREC.MED. EO-34 ranked by their market capitalization.

Company	Market Cap
RONSHINE CH.HLD.HD-00001 F:1R7	$7.87 Million
Alliance Developpement Capital SIIC SE PA:ALDV	$7.88 Million
HUIJING HLDG.CO.LTD HD-01 F:3XU	$7.88 Million
Torr Metals Inc V:TMET	$7.88 Million
Sanginita Chemicals Limited NSE:SANGINITA	$7.86 Million
Tenon Medical Inc NASDAQ:TNON	$7.86 Million
Emerson Radio Corporation NYSE MKT:MSN	$7.86 Million
XOX Technology Bhd KLSE:0017	$7.85 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ONCODES.PREC.MED. EO-34's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 3,690,701 to -429,389, a change of -4,120,089 (-111.6%).
Net loss of 7,209,619 reduced equity.
Other factors increased equity by 3,089,530.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-7.21 Million	-1679.04%
Other Changes	€3.09 Million	+719.52%
Total Change	€-	-111.63%

Book Value vs Market Value Analysis

This analysis compares ONCODES.PREC.MED. EO-34's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2021-12-31	€0.61	€0.35	x
2022-12-31	€0.71	€0.35	x
2023-12-31	€0.22	€0.35	x
2024-12-31	€-0.02	€0.35	x

Capital Efficiency Dashboard

This dashboard shows how efficiently ONCODES.PREC.MED. EO-34 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -3482.24%
• Asset Turnover: 0.02x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-72.82%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2021	-70.10%	-76.86%	0.46x	1.99x	€-3.36 Million
2022	-1.96%	-2.90%	0.43x	1.56x	€-1.41 Million
2023	-219.22%	-754.61%	0.06x	4.51x	€-8.46 Million
2024	0.00%	-3482.24%	0.02x	0.00x	€-7.17 Million

Industry Comparison

This section compares ONCODES.PREC.MED. EO-34's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $223,512,703
Average return on equity (ROE) among peers: -29.10%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
ONCODES.PREC.MED. EO-34 (ZR8)	€-	-70.10%	N/A	$7.87 Million
PROQR THERAPEUTICS EO-04 (0PQ)	$49.37 Million	-85.44%	1.28x	$142.34 Million
TIZIANA LIFE SCIENCES LTD (0RP)	$41.28 Million	-56.73%	0.18x	$161.62 Million
Theravance Biopharma Inc (0TB)	$-303.75 Million	0.00%	0.00x	$823.46 Million
I-MAB SPONS.ADS/1 -0001 (0VY)	$715.33 Million	-51.14%	0.23x	$212.27 Million
PreveCeutical Medical Inc (18H)	$-4.49 Million	0.00%	0.00x	$3.34 Million
Argen-X (1AE)	$344.93 Million	-8.14%	0.08x	$41.67 Billion
WAVE LIFE SCIENCES LTD. (1U5)	$518.36 Million	-39.43%	0.23x	$1.14 Billion
BIOCURE TECHNOLOGY INC. (1WH)	$1.34 Million	-19.58%	0.49x	$960.84K
ZAI LAB LTD0000006 (1ZLB)	$840.90 Million	-30.57%	0.41x	$1.82 Billion
BioNTech SE (22UA)	$31.86 Million	0.00%	11.24x	$20.05 Billion

About ONCODES.PREC.MED. EO-34

F:ZR8 Germany Biotechnology

Market Cap

$7.87 Million

€6.73 Million EUR

Market Cap Rank

#27614 Global

#2399 in Germany

Share Price

€0.35

Change (1 day)

-7.59%

52-Week Range

€0.27 - €0.78

All Time High

€2.20